Mercer Global Advisors
KNSA icon

Mercer Global Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Mercer Global Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$574K Buy
8,973
+13
+0.1% +$674 ﹤0.01% 2169
2026
Q1 		$431K Buy
8,960
+1,276
+17% +$56.5K ﹤0.01% 2096
2025
Q4 		$317K Buy
7,684
+508
+7% +$20.4K ﹤0.01% 2189
2025
Q3 		$279K Sell
7,176
-95
-1% -$3.09K ﹤0.01% 2144
2025
Q2 		$201K Buy
+7,271
New +$185K ﹤0.01% 2078
2024
Q4 		– Sell
-9,609
Closed -$245K – 2202
2024
Q3 		$245K Sell
9,609
-6,981
-42% -$170K ﹤0.01% 1699
2024
Q2 		$310K Sell
16,590
-1,099
-6% -$20.6K ﹤0.01% 1557
2024
Q1 		$349K Sell
17,689
-1,095
-6% -$21.4K ﹤0.01% 1480
2023
Q4 		$329K Buy
18,784
+1,626
+9% +$26.7K ﹤0.01% 1551
2023
Q3 		$298K Sell
17,158
-6,066
-26% -$102K ﹤0.01% 1539
2023
Q2 		$327K Buy
23,224
+5,058
+28% +$67.7K ﹤0.01% 1464
2023
Q1 		$195K Buy
+18,166
New +$239K ﹤0.01% 1741

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Mercer Global Advisors's KNSA Position: Q2 2026 in Review

Mercer Global Advisors increased its Kiniksa Pharmaceuticals (KNSA) stake by 0.15% in Q2 2026, buying an estimated $674 and bringing the position to 8,973 shares worth $574K. The position accounts for ﹤0.01% of the portfolio, ranked #2169.

Mercer Global Advisors first reported a position in KNSA in Q1 2023 and has held it in 12 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Mercer Global Advisors held 8,973 shares of Kiniksa Pharmaceuticals worth $574K as of Q2 2026.
  • Mercer Global Advisors bought 13 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $674.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2169 holding.
  • Mercer Global Advisors first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.